Low-intensity systemic inflammation and type 2 diabetes mellitus: new therapy options

Low-grade systemic inflammation (LSSI) is a key factor in the onset and progression of type 2 diabetes mellitus (T2DM) and associated cardiovascular diseases (CVD). Indeed, inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and IL-6 are known to predict the development of T2DM and its complications. Overeating, unhealthy diet, physical inactivity, obesity, and aging are recognized triggers of LSSI that contribute to insulin resistance and participate in the pathogenesis of T2DM. After the development of T2DM, hyperglycemia, dyslipidemia, accumulation of senescent cells, stimulation of immune cells, changes in trained immunity, meta-inflammation, and renal dysfunction maintain LSSI and increase the risk of vascular pathology. However, the effect on inflammatory processes is not included in traditional T2DM treatment regimens. On the other hand, individual disease-modifying drugs, such as glucagon-like peptide type 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors, appear to reduce systemic inflammation and may prevent the development of T2DM and CVD when administered early. In addition, the effect of other anti-inflammatory drugs on SIDS in patients with T2DM is being studied. This literature review is devoted to the analysis of literature data on the role of SIDS in the development and progression of T2DM, CVD, as well as the role of anti-inflammatory and hypoglycemic drugs in the prevention of SIDS, T2DM (and/or its compensation).

Authors

Institutions

Publication Details

Journal
Экспериментальная и клиническая гастроэнтерология
Published
2026-11-18
DOI
https://doi.org/10.31146/1682-8658-ecg-248-4-181-189
Primary Topic
Adipokines, Inflammation, and Metabolic Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Low-intensity systemic inflammation and type 2 diabetes mellitus: new therapy options

E. V. Treneva, Svetlana Viktorovna Bulgakova, Dmitrii P. Kurmaev
2 links
Экспериментальная и клиническая гастроэнтерология
Adipokines, Inflammation, and Metabolic Diseases
article

Low-intensity systemic inflammation and type 2 diabetes mellitus: new therapy options

E. V. Treneva, Svetlana Viktorovna Bulgakova, Dmitrii P. Kurmaev
article en

Abstract

Low-grade systemic inflammation (LSSI) is a key factor in the onset and progression of type 2 diabetes mellitus (T2DM) and associated cardiovascular diseases (CVD). Indeed, inflammatory markers such as high-sensitivity C-reactive protein (hs-CRP) and IL-6 are known to predict the development of T2DM and its complications. Overeating, unhealthy diet, physical inactivity, obesity, and aging are recognized triggers of LSSI that contribute to insulin resistance and participate in the pathogenesis of T2DM. After the development of T2DM, hyperglycemia, dyslipidemia, accumulation of senescent cells, stimulation of immune cells, changes in trained immunity, meta-inflammation, and renal dysfunction maintain LSSI and increase the risk of vascular pathology. However, the effect on inflammatory processes is not included in traditional T2DM treatment regimens. On the other hand, individual disease-modifying drugs, such as glucagon-like peptide type 1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter 2 inhibitors, appear to reduce systemic inflammation and may prevent the development of T2DM and CVD when administered early. In addition, the effect of other anti-inflammatory drugs on SIDS in patients with T2DM is being studied. This literature review is devoted to the analysis of literature data on the role of SIDS in the development and progression of T2DM, CVD, as well as the role of anti-inflammatory and hypoglycemic drugs in the prevention of SIDS, T2DM (and/or its compensation).

Экспериментальная и клиническая гастроэнтерология(4)
Samara State Medical University (RU)
Good health and well-being
Adipokines, Inflammation, and Metabolic Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon